-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $45

Benzinga·05/14/2025 14:36:51
Listen to the news
Wells Fargo analyst Yanan Zhu maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and lowers the price target from $50 to $45.